Sanofi has committed $30 million to Cincinnati‑based Enable Injections, a company that builds the enFuse On‑Body Delivery System (OBDS). The capital injection is intended to speed up Enable’s manufacturing build‑out, strengthen its supply‑chain capabilities, and support the commercial growth of the OBDS platform across Sanofi’s product pipeline.
The OBDS delivers large‑volume subcutaneous therapies through a small, retractable needle, a technology that Sanofi has already deployed in its Sarclisa IRAKLIA phase 3 trial and the IZALCO phase 2 study for multiple myeloma. By expanding Enable’s manufacturing capacity, Sanofi aims to meet the rising demand for subcutaneous biologics and position the OBDS as a key delivery solution for future therapies, including potential new indications for Sarclisa and other large‑volume biologics.
Enable has raised significant capital in the past, including a $50 million Series B led by Sanofi in 2018 and a $215 million Series C in January 2022. The new investment builds on that partnership and provides the resources needed to scale production to the volumes required for commercial launch. Michael D. Hooven, Chairman and CEO of Enable, said the funding “will accelerate our manufacturing capabilities and enable us to meet the needs of our partners while bringing innovative treatment options to patients worldwide.”
Sanofi’s broader strategy includes a $20 billion pledge for U.S. R&D and manufacturing by 2030 and an additional $625 million commitment to its venture arm to accelerate biotech and digital health innovation. The OBDS investment aligns with that strategy by enhancing Sanofi’s supply‑chain resilience and expanding its delivery portfolio in a market projected to grow as patients and clinicians favor convenient, self‑administered biologics.
The subcutaneous biologics market is expanding as chronic disease prevalence rises and patients demand easier administration. By securing a stronger relationship with Enable and investing in manufacturing capacity, Sanofi is positioning itself to capture a larger share of this market and to support the commercial launch of new therapies that can be delivered through the OBDS platform.
The investment underscores Sanofi’s confidence in the OBDS technology and its potential to become a cornerstone of the company’s future product pipeline, reinforcing its competitive positioning in the subcutaneous biologics arena.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.